R. Session
Direktor/Vorstandsmitglied bei Lung Therapeutics, Inc.
Aktive Positionen von R. Session
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Lung Therapeutics, Inc.
 Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Direktor/Vorstandsmitglied | 04.02.2019 | - |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Direktor/Vorstandsmitglied | - | - |
| Sandhill Therapeutics, Inc. | Direktor/Vorstandsmitglied | - | - |
Society of Kauffman Fellows
 Society of Kauffman Fellows Miscellaneous Commercial ServicesCommercial Services The Society of Kauffman Fellows is a venture capital fellowship program that aims to foster innovative leaders. The non-profit company is based in Palo Alto, CA. The program lasts for two years and includes industry events, summits, and a venture capital fund. The CEOs of the company are Jeff Harbach, Costello Trish. | Corporate Officer/Principal | - | - |
Karriereverlauf von R. Session
Ehemalige bekannte Positionen von R. Session
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Direktor/Vorstandsmitglied | 20.09.2019 | 02.03.2023 |
| Vorstandsvorsitzender | 20.09.2019 | 16.12.2022 | |
| Gründer | 20.09.2019 | 02.03.2023 | |
| Präsident | 20.09.2019 | 16.12.2022 | |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 01.01.2019 | 01.04.2020 |
| 4D MOLECULAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01.08.2018 | 01.12.2018 |
| AVEXIS INC | Corporate Officer/Principal | 01.03.2017 | 01.07.2018 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01.10.2013 | 01.03.2017 |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von R. Session
| Texas A&M University | Graduate Degree |
| The University of North Carolina at Charlotte | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 14 |
Operativ
| Corporate Officer/Principal | 6 |
| Director/Board Member | 5 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 9 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | Health Technology |
Chardan Healthcare Acquisition 2 Corp.
 Chardan Healthcare Acquisition 2 Corp. Financial ConglomeratesFinance Chardan Healthcare Acquisition 2 Corp. operates as a blank check company, which engages in the acquisition of healthcare company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on December 19, 2018 and is headquartered in New York, NY. | Finance |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
| Sandhill Therapeutics, Inc. | |
Society of Kauffman Fellows
Society of Kauffman Fellows Miscellaneous Commercial ServicesCommercial Services The Society of Kauffman Fellows is a venture capital fellowship program that aims to foster innovative leaders. The non-profit company is based in Palo Alto, CA. The program lasts for two years and includes industry events, summits, and a venture capital fund. The CEOs of the company are Jeff Harbach, Costello Trish. | Commercial Services |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
- Börse
- Insiders
- R. Session
- Erfahrung
